Generare operates an industrial‑scale platform that extracts, purifies, identifies, and annotates previously unread microbial metabolites directly from their natural contexts, creating high‑quality molecular data that have never been seen by AI models or researchers. By unlocking the 97% of microbial chemistry hidden from traditional libraries, the company supplies pharmaceutical and biotech partners with novel, evolution‑derived scaffolds for rapid development of first‑in‑class drug candidates across areas such as antibiotics and oncology.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery relies heavily on known chemical libraries, but the vast majority of microbial chemistry—shaped by billions of years of evolution—remains inaccessible, limiting the pool of novel bioactive compounds for new therapeutics.
Solution
Generare provides an industrial-scale platform that extracts, purifies, identifies, and annotates previously unread microbial molecules directly from their natural biological contexts. By unearthing this hidden 97% of microbial chemistry, the company creates unique, high‑quality molecular data that have never been seen by AI models or researchers. Each newly discovered compound is characterized for its natural function, enabling rapid translation into first‑in‑class drug candidates across therapeutic areas such as antibiotics and oncology. The continuously expanding proprietary dataset improves predictive selection, creating a feedback loop that accelerates the discovery of novel, evolution‑derived medicines.
Target Audience
Generare serves pharmaceutical companies and biotech firms seeking novel, biologically active scaffolds for antibiotic, oncology, and other therapeutic pipelines.
Features
- Large‑scale extraction and purification workflow that isolates native microbial metabolites at industrial throughput
- Comprehensive analytical pipeline for structural identification and functional annotation of unknown molecules
- Proprietary data generation that adds unique, never‑before‑trained data points to AI‑driven drug discovery models
- Integrated platform that links molecule discovery to downstream drug development, supporting rapid lead optimization
- Continuous learning loop where each new compound enriches the dataset, enhancing future selection accuracy